Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx-Reference-Cited by-同舟云学术

Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx

Published:2020-02-06 Issue:3 Volume:4 Page:477-481
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Carden Marcus A.¹²,Gaddh Manila³⁴,Hoskote Abhinav⁵,Brown Michael³,Merrill Virginia³,Stowell Sean R.⁶⁷,Chandrakasan Shanmuganathan⁸,Antun Ana³⁴,Kudchadkar Ragini³⁴,Kotanchiyev Sarah⁷,Jaye David L.³⁷,Bodó Imre³⁴⁹

Affiliation:

1. Division of Pediatric Hematology/Oncology and

2. Division of Medical Hematology, School of Medicine, University of North Carolina, Chapel Hill, NC;

3. Winship Cancer Institute and

4. Department of Hematology and Medical Oncology, School of Medicine, Emory University, Atlanta, GA;

5. Department of Medicine, Mount Sinai Saint Luke’s Hospital, New York, NY;

6. Emory Center for Transfusion Medicine and Cellular Therapies, Atlanta, GA;

7. Department of Pathology and Laboratory Medicine, School of Medicine, and

8. Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, School of Medicine, Emory University, Atlanta, GA; and

9. 3rd Department of Medicine, Semmelweis University, Budapest, Hungary

Abstract

Key Points How TPEx impacts rituximab effectiveness in iTTP patients is not fully understood. In iTTP patients on therapeutic plasma exchange, rituximab eliminates circulating CD20+ B and T cells in 24 hours for at least 1 week.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/4/3/477/1719317/advancesadv2019001148.pdf

Reference25 articles.

1. Thrombotic thrombocytopenic purpura;Joly;Blood,2017

2. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura;Moake;N Engl J Med,1982

3. Pathophysiology of thrombotic thrombocytopenic purpura;Sadler;Blood,2017

4. How I treat patients with thrombotic thrombocytopenic purpura: 2010;George;Blood,2010

5. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura;Scully;Blood,2011

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ADAMTS13 in the New Era of TTP;International Journal of Molecular Sciences;2024-07-26

2. Plasma cell‐directed therapy strategies in immune‐mediated thrombotic thrombocytopenic purpura (iTTP);Transfusion;2024-01-18

3. Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review;British Journal of Haematology;2023-08-12

4. Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis;Cancers;2023-02-09

5. CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties;Scientific Reports;2021-10-15